| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:RLX-33
CAS:2784577-71-3
Purity:98% Package:10mg Remarks:S23828
|
| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:RLX-33
CAS:2784577-71-3
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
3-Pyrrolidinecarboxamide, N-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-1-(2-furanylmethyl)-5-oxo- manufacturers
- RLX-33
-
- $75.00 / 1mg
-
2025-11-09
- CAS:2784577-71-3
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| | 3-Pyrrolidinecarboxamide, N-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-1-(2-furanylmethyl)-5-oxo- Basic information |
| | 3-Pyrrolidinecarboxamide, N-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-1-(2-furanylmethyl)-5-oxo- Chemical Properties |
| density | 1.412±0.06 g/cm3(Predicted) | | pka | 13.12±0.70(Predicted) | | form | Solid | | color | White to light yellow |
| | 3-Pyrrolidinecarboxamide, N-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-1-(2-furanylmethyl)-5-oxo- Usage And Synthesis |
| Uses | RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome[1]. | | in vivo | RLX-33 (10 mg/kg; IP, single dosage) attenuates the RXFP3-selective agonist R3/I5-induced increase in feeding in male Wistar rats[1].
RLX-33 (10 mg/kg; IP, single dosage) exhibits a good brain penetration and highly protein-bound in rats plasma[1].
Pharmacokinetic Parameters of RLX-33 in male Wistar rats (IP, 10 mg/kg)[1].
| plasma | brain | | Cmax (ng/mL) | 1401 | 1552 | | tmax (h) | 0.5 | 2.0 | | t1/2 (h) | 1.9 | 4.9 | | AUCinf (ng/mL·h) | 5352 | 12519 | | CL_F (mL/min/kg) | 43.8 | |
| Animal Model: | Male Wistar rats (intracerebroventricular administration of R3/I5 stimulated food intake[1] | | Dosage: | 10 mg/kg | | Administration: | IP, single dosage | | Result: | Attenuated the R3/I5-induced increase in food intake. |
| Animal Model: | Male Wistar rats[1] | | Dosage: | 10 mg/kg | | Administration: | IP, single dosage (Pharmacokinetic Analysis) | | Result: | Exhibited a good brain penetration and highly protein-bound, with protein binding of 99.8% in rat plasma. |
| | References | [1] https://pubmed.ncbi.nlm.nih.gov/35594150/ DOI:10.1021/acs.jmedchem.2c00508 |
| | 3-Pyrrolidinecarboxamide, N-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-1-(2-furanylmethyl)-5-oxo- Preparation Products And Raw materials |
|